Pierre Fabre Pharmaceuticals Announce Initiation of Phase IIa Clinical Trial Program for F17464 in Schizophrenia
Advertisement
Pierre Fabre Pharmaceuticals announce the initiation of a Phase IIa clinical trial program for F17464, a new selective dopamine D3 receptor antagonist, in schizophrenia. The trial is designed to assess the efficacy and safety of F17464 compared to placebo in patients with acute schizophrenia. The six-week multinational European trial will enroll 142 patients. This development is a reflection of Pierre Fabre Laboratories’ strategy to invest in R&D on priority franchises such as neuropsychiatry, oncology and dermatology.
"After the marketing authorization issued in 2013 by the FDA to Forest Laboratories, Inc. now Actavis, plc for Fetzima® -levomilnacipran an active compound discovered by the Pierre Fabre Research Institute ; we welcome this new step with another molecule from our R&D experts' research into the central nervous system. The originality of this new molecule and the initial pharmacodynamics and safety results are extremely encouraging," declared Frédéric Duchesne, President of Pierre Fabre Pharmaceuticals.